Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash
Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last year investing.com. This record top-line was boosted by a one-time $275 M licensing deal with partner Sobi investing.com, which paid Apellis upfront for future ex-U.S. royalties on Aspaveli (Empaveli’s overseas brand). Thanks largely to this deal, Apellis swung to a net profit of $215.7 M (versus a $57.4 M loss a year ago) markets.businessinsider.com. However,
